1. 2020
  2. Design and Performance of the first IceAct Demonstrator at the South Pole

    IceCube-Gen2 Collaboration, Coppin, P., Toscano, S., Eijndhoven, N. V., Correa Camiroaga, P., De Clercq, C., De Wasseige, G. L., De Vries, K. & Maggi Olmedo, G. A., 4 Feb 2020, In : JINST. 15, 27 p., T02002.

    Research output: Contribution to journalArticle

  3. 2015
  4. 2013
  5. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

    Hu, J., Van Valckenborgh, E., Xu, D., Menu, E., De Raeve, H., De Bruyne, E., Xu, S., Van Camp, B., Handisides, D. R., Hart, C. & Vanderkerken, K., 5 Jul 2013, In : Mol Cancer Ther. 12, 9, p. 1763-1773 11 p.

    Research output: Contribution to journalArticle

  6. The role of Notch signaling in multiple myeloma

    Xu, D., Hu, J., De Bruyne, E., Menu, E., Vanderkerken, K. & Van Valckenborgh, E., 9 Jan 2013, Genetic and Molecular Epidemiology of Multiple Myeloma. Lentzsch, S. (ed.). Springer, p. 77-95 19 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter

  7. 2012
  8. Dll1/Notch Interaction Contributes to a Decreased Sensitivity of Myeloma Cells to Bortezomib

    Xu, D., Hu, J., De Bruyne, E., Menu, E., Schots, H., Vanderkerken, K. & Van Valckenborgh, E., Dec 2012, In : Blood. 120, 21, p. 1840-1840 1 p.

    Research output: Contribution to journalConference paper

  9. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.

    Xu, D., Hu, J., De Bruyne, E., Menu, E., Schots, H., Vanderkerken, K. & Van Valckenborgh, E., 27 Oct 2012, In : Biochem Biophys Res Commun. 428, 4, p. 518-524 7 p.

    Research output: Contribution to journalArticle

  10. Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model.

    Van Valckenborgh, E., Matsui, W., Agarwal, P., Lub, S., Xu, D., De Bruyne, E., Menu, E., Empsen, C., Van Grunsven, L., Agarwal, J., Wang, Q., Jernberg-Wiklund, H. & Vanderkerken, K., 6 Jan 2012, In : Leukemia. 26, 6, p. 1436-1439 4 p.

    Research output: Contribution to journalArticle

  11. 2011
  12. Activation of ATF4 mediates the unwanted Mcl-1accumulation by proteasome inhibition.

    Hu, J., Dang, N., Menu, E., De Bruyne, E., Xu, D., Van Camp, B., Van Valckenborgh, E. & Vanderkerken, K., 29 Nov 2011, In : Blood. 119, 2012, p. 826-837 12 p.

    Research output: Contribution to journalArticle

Previous 1 2 Next

ID: 172570